盛美上海(688082.SH):控股股東ACMR將進行分拆股份事項
格隆匯3月16日丨盛美上海(688082.SH)公佈,此次公吿涉及的公司控股股東ACM Research, Inc. (“ACMR”,股票代碼ACMR)分拆股份事項,根據ACMR適用的法律法規及章程有關規定,已經由ACMR董事會批准,ACMR將以股票股息的形式對ACMR的股票(包括A類普通股和B類普通股)按1:3的比例進行分拆和分配。ACMR的A類普通股將於當地時間2022年3月24日在分拆後的股份基礎上進行交易。分拆股份完成後,ACMR的控股股東HUI WANG仍為ACMR的控股股東和公司的實際控制人,分拆股份不影響其持有ACMR的股份佔比情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.